Related Experiment Videos
Endothelial cell activation by antiphospholipid antibodies
P L Meroni1, E Raschi, C Testoni
1Allergy, Clinical Immunology and Rheumatology Unit, IRCCS Istituto Auxologico Italiano, Department of Internal Medicine, University of Milan, Milan, Italy. pierluigi.meroni@unimi.it
Clinical Immunology (Orlando, Fla.)
|July 9, 2004
Summary
Antiphospholipid antibodies target beta 2 glycoprotein I, activating endothelial cells and contributing to thrombosis. Molecular mimicry with microbial structures may trigger inflammatory signaling via Toll-like receptors.
Area of Science:
- Immunology
- Vascular Biology
Background:
- Antiphospholipid antibodies (aPL) are key players in antiphospholipid syndrome (APS).
- Beta 2 glycoprotein I (β2GPI) is a primary target antigen for aPL.
- Endothelial cell activation by aPL contributes to the prothrombotic state in APS.
Purpose of the Study:
- To elucidate the mechanisms by which anti-β2GPI antibodies induce endothelial activation.
- To investigate the role of annexin II and Toll-like receptors (TLRs) in anti-β2GPI antibody-mediated endothelial dysfunction.
Main Methods:
- In vitro and in vivo experimental models were used to study antibody binding and endothelial cell responses.
- Analysis of mRNA expression for pro-inflammatory mediators.
- Investigation of NF-κB translocation and TLR signaling pathways.
Main Results:
- Antibody binding to β2GPI on endothelial cells triggers endothelial activation.
- β2GPI adhesion to endothelial cells involves electrostatic interactions and annexin II.
- Anti-β2GPI antibodies up-regulate pro-inflammatory mediators via NF-κB and TLR signaling.
Conclusions:
- Anti-β2GPI antibodies promote a prothrombotic state through endothelial activation.
- Molecular mimicry between β2GPI and microbial structures may explain TLR involvement.
- Targeting these pathways could offer therapeutic strategies for APS.